Toward the establishment of a clinical prediction rule for response of prolactinomas to cabergoline.
Verhelst
J A
JA
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000077465:Cabergoline; D004873:Ergolines / Q000627:therapeutic use*; D006801:Humans; D010911:Pituitary Neoplasms / Q000188:drug therapy*; D015175:Prolactinoma / Q000188:drug therapy*
D000970:Antineoplastic Agents; D004873:Ergolines; D000077465:Cabergoline